Skip to content

REtinal Detachment Outcomes Study

Rhegmatogenous rEtinal Detachment With or withOut Scleral Buckle (REDOS) Trial: a Factorial, Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05863312
Acronym
REDOS
Enrollment
560
Registered
2023-05-18
Start date
2023-09-26
Completion date
2028-07-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Detachment

Keywords

Pars plana vitrectomy, Scleral buckle, Rhegmatogenous retinal detachment, Proliferative vitreoretinopathy, Anatomic success, Visual acuity, Retinal displacement, Postoperative pain, Quality of life, Complications

Brief summary

Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade. Methods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results. Discussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.

Interventions

PROCEDUREPars plana vitrectomy

Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.

PROCEDUREPars plana vitrectomy with scleral buckle

In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.

OTHERSulfur hexafluoride gas tamponade

At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.

OTHERPerfluoropropane gas

At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.

Sponsors

Fighting Blindness Canada
CollaboratorUNKNOWN
CHU de Quebec-Universite Laval
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Diagnosis of rhegmatogenous retinal detachment

Exclusion criteria

, retinal detachment with: * Proliferative vitreoretinopathy (PVR) grade ≥C2 * Chronic RRD with duration \>3 months * Proliferative diabetic retinopathy with tractional retinal detachment (RD) * Macular holes * Epiretinal membrane grade 3 or 4 * Traumatic RD * Giant retinal tears * Retinal dialysis * Foveoschisis * Wet age-related macular degeneration * Endophthalmitis * Acute retinal necrosis * Coats disease * Retinopathy of prematurity * Retinoschisis * Retinal colobomas * Prior glaucoma surgery or strabismus surgery (favoring PPV only) * Superior RD extent less than 3 clock hours (favoring PPV only)

Design outcomes

Primary

MeasureTime frameDescription
Single surgery anatomic successUntil final 1 year follow-upFreedom from reoperation for recurrent RRD

Secondary

MeasureTime frame
Pinhole visual acuity8-10 weeks, 6 months
Best-corrected visual acuity1 year
Time to onset of RD recurrenceUntil final 1 year follow-up
Severity and number of complicationsUntil final 1 year follow-up
Quality of life questionnaire2 weeks, 8-10 weeks, 6 months, 12 months

Countries

Canada

Contacts

Primary ContactJulie Mauger, BSc
cuo.recherche@fmed.ulaval.ca418-682-7511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026